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Abstract
The proteoliposome derived from Vibrio cholerae O1 (PLc) is a nanoscaled structure obtained by a detergent
extraction process. Intranasal (i.n) administration of PLc was immunogenic at mucosal and systemic level vs. V.
cholerae; however the adjuvant potential of this structure for non-cholera antigens has not been proven yet. The
aim of this work was to evaluate the effect of coadministering PLc with the Vi polysaccharide antigen (Poli Vi) of S.
Typhi by the i.n route. The results showed that Poli Vi coadministered with PLc (PLc+Poli Vi) induce a higher IgA
response in saliva (p<0.01) and faeces (p<0.01) than Poli Vi administered alone. Likewise, the IgG response in sera
was higher in animals immunised with PLc+Poli Vi (p<0.01). Furthermore, IgG induced in sera of mice immunised
with PLc+Poli Vi was similar (p>0.05) to that induced in a group of mice immunised by the parenteral route with
the Cuban anti-typhoid vaccine vax-TyVi®, although this vaccine did not induce a mucosal response. In conclusion,
this work demonstrates that PLc can be used as a mucosal adjuvant to potentiate the immune response against a
polysaccharide antigen like Poli Vi.
Background
Enteric infections induced by pathogens are one of the
main causes of death all over the world [1]. Vibrio cholerae
kills more than 100 000-130 000 persons each year, most
of them children and adolescents between 5 and 19 years
old. Current vaccines are mainly based on attenuated or
inactivated whole bacterial cells [1]. Alternatively, our
group has been working on the development of a non-liv-
ing adjuvant/delivery strategy based on PLc, a proteolipo-
some-like structure extracted from the strain C7258 of V.
cholerae O1 El Tor Ogawa [2]. PLc contain important
antigens and immunostimulatory molecules like lipopoly-
saccharides (LPS), OmpU porin and MSHA. Recent work
demonstrated that PLc induced a higher IgA response in
mucosal fluids as well as IgG in sera against V. cholerae
antigens; furthermore the vibriocidal activity of sera of
mice immunized with PLc [2] encouraged our group to
further study the potential immunoadjuvant properties of
this structure. Proteoliposomes derived from bacteria have
also been used as an adjuvant to potentiate the immune
response against heterologous antigens [3], particularly a
Neisseria derived proteosome has been used to increase
the immunogenicity of LPS from Shigella flexneri [4].
Therefore we thought to evaluate the adjuvant potential of
PLc for the capsular polysaccharide Vi of S. Typhi (Poli
Vi). Typhoid fever caused by invasion of S. Typhi through
enteric mucosa constitutes also a health problem; every
year more than 500 000 persons die and most of them are
children about 5- 19 years old from developing countries
[1]. Strategies based on attenuated whole cell vaccines or
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purified Poli Vi vaccines have not been able to prevent
Typhoid fever especially in infants [1].
Materials and methods
Antigens and vaccines. PLc was obtained from the
V. cholerae C7258 strain using a detergent protocol of
extraction, reported by Pérez JL et al. [2]. The structural
characterization was carried out using electron micro-
scopy, photon correlation spectroscopy and zeta potential
analysis. PLc composition was evaluated by Lowry pro-
tein assay and western blot (MSHA, LPS and OmpU) as
later described [5]. Poli Vi (lot 8003) administered alone
or coadministered with PLc and the vaccine vax-TyVi®
(lot 9009) were supplied by Finlay Institute, Havana,
Cuba.
Immunization and sample collection
Female BALB/c mice (6-8 weeks old, CENPALAB, Cuba)
were immunized with a three-dose schedule, 7 days apart
(0, 7, 14). Each dose of 20 μL contained 100 μg of PLc
plus Poli Vi 25 μg and was administered to mice by i.n
route without anesthesia (10 μL per nostril). Control
groups with Poli Vi alone were administered with the
same schedule by the i.n route (25 µg per dose per mouse)
or one intramuscular (i.m) dose of vax-TyVi® (5 µg per
dose per mouse). Placebo control groups were immunized
with PBS buffer. Samples were collected 7 days (saliva and
faeces) or 14 days (sera) after the last dose as described
elsewhere [5]. Animals were housed at the Finlay Institute
animal facility. The experiment was performed by dupli-
cate and with approval of the Finlay Institute Ethical
Committee.
Determination of antibodies by ELISA
IgG anti-Poli Vi antibodies in serum samples and IgA
anti-Poli Vi antibodies in saliva and faeces were mea-
sured by indirect ELISA as described elsewhere [6].
Briefly, PoliSorp plates (Nunc, Roskilde, Denmark) were
set 1 h at room temperature (20-25°C) with poli-L-
Lysine at 3 μg/mL (100 μL per well) and then coated
with Poli Vi (100 μL per well) at 5 μg/mL. Serum sam-
ples were diluted 1:100 and saliva and faeces 1:2 (in PBS
supplemented with 1% (w/v) BSA). Peroxidase anti-
mouse IgG, or anti mouse IgA were used as secondary
antibodies. O-phenylene diamine (OPD) was used as the
substrate to detect antibodies bound to the antigen.
Optical densities were read at 492 nm using an ELISA
reader (Titertek Multiskan®).
Statistical methods
Analysis of data was carried out using ANOVA. Post
test multiple comparison was performed with Graph
Pad Prism 4 software (CA, USA).
Results
PLc extraction and characterization
PLc structures were obtained from the virulent strain of
C7258, V. cholerae O1, El Tor Ogawa using the detergent
extraction protocol and observed by TEM (Figure 1A).
The polydispersion index of the vesicles was 0.4 and they
had a mean size of 156.9 ± 22.2 nm. Their surface charge
was estimated at -23.8 ± 1.21 mV. The amount of LPS
calculated by densitometric/western analysis was 0.28 ±
0.06 mg per 1 mg of total protein in PLc. MSHA and
OmpU protein antigens, were also identified by the wes-
tern blot method (Figure 1B).
Effect of coadministration of PLc and Poli Vi
PLc+Poli Vi coadministered by i.n route induced higher
anti-Poli Vi IgA in saliva and faeces than the groups
immunised with Poli Vi (i.n) alone or with vax-TyVi® by
i.m route (Figure 2A). Likewise, PLc+Poli Vi induced higher
anti-Poli Vi IgG in sera than Poli Vi administered alone
(Figure 2B). Interestingly, specific IgG anti-Poli Vi in sera
induced by i.n PLc+Poli Vi formulation was comparable
with that induced by one dose of vax-TyVi® administered
by the i.m route (Figure 2B).
Discussion
Mucosal surfaces constitute one of the most important
points of entry of infectious agents; protection against
infections requires the induction of immune responses at
mucosal level [7]. Polysaccharides and LPS from enteric
pathogens are considered as some of the most important
antigens to induce protection [8]. However, their mucosal
administration has proven to be inefficient for the stimu-
lation of the immune system [8]. Mucosal adjuvants can
overcome this problem and potentiate their immune
responses [9]. Protollin is a complex mix of outer mem-
brane proteins from Neisseria meningitidis B and LPS
from Shiguella flexneri (proteosome), this formulation
was administered by the i.n route to humans and mice
and improved the immune response against LPS antigen
[4,10]. Therefore, we evaluated the effect of coadminis-
tration of PLc with Poli Vi by the i.n route.
Results showed that proteoliposomes extracted from
V. cholerae O1 (Figure 1A) contain immunogenic and
immunostimulatory molecules like OmpU, MSHA and
LPS (Fig 1B). Coadministration of PLc with the polysac-
charide improves the mucosal and systemic immune
response induced vs. Poli Vi (Figure 2) without affecting
the immune response vs V. cholerae antigens (results
not shown). Purified Poli Vi antigen has been used in
the formulation of a parenteral vaccine against typhoid
fever [11] but has never been used by a mucosal route
as a with vaccine purposes. Mucosal immunization has
been approached by administration by the oral route of
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Figure 1 Characterization of PLc derived from V. cholerae O1. Micrograph in A was obtained by TEM and shows vesicle shape of PLc.
B shows the main antigens identified in PLc by Western Blot: Lanes 1 to 3 represent blotted PLc (5 μg) and Lane 4 the biotinylated molecular
weight pattern. Each Line was treated with different Mabs. (Lane 1): MAb 2F12F1 (anti MSHA), (Lane 2): MAb 9H12E6 (anti OmpU) and (Lane 3):
MAb 2B4G5 (anti O-p-LPS Ogawa). Band centered for LPS is ~30 kDa (Lane 3), OmpU~38 kDa (Lane 2) and MSHA~17 kDa (Lane 1).
Figure 2 Specific IgA (A) and IgG (B) anti Poli Vi antibody response in mice samples. 25 μg of Poli Vi (12.5 μg each nostril) was administered
with or without PLc (50 μg each nostril) in BALB/c mice (n=5) by the intranasal route (10 μL per nostril). A three-dose schedule (0, 7 and 14 days) was
used and samples were evaluated. Vax-TyVi vaccine was used as a positive control with only one dose by the i.m. route. (A): Seven days after the last
immunization, saliva (white columns) and faeces (black columns) were collected and diluted 1:2. Results are expressed as a mean of optical density
units (OD) ± standard deviation. (B): Fourteen days after the last immunization, sera was obtained and diluted 1:100. Results are expressed as a mean
of optical density units (OD) ± standard deviation. A placebo group was also included in each experiment and the effect was subtracted for statistical
analysis. Tukey test was used to analyze the data of two experiments. P values indicate significant differences between groups.
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the attenuated S. Typhi strain CVD 909 (HolaVax-
Typhoid®) expressing the Vi polysaccharide [7]. In these
experiments the systemic immune response was superior
to that induced by the attenuated S. Typhi strain Ty21a
which do not express Poli Vi [12]. Ty21a is also the strain
used in the licensed vaccine Vivotif®, against typhoid
fever [7]. Specific IgG anti Poli Vi in sera is crucial to
avoid pathogen invasion to macrophages and evasion
from immunocompetent cells [13]. The role of IgA anti
Poli Vi may also be related to the blockade of pathogen
invasion at a mucosal level [13], however the mechanisms
of the protection induced by our formulation needs to be
evaluated.
The use of mucosal vaccines has many advantages when
compared to parenteral administration. Particularly, if vac-
cine formulations are intended against pathogens that
colonize or invade via the mucosal route, like V. cholerae
and S. Typhi [8]. Mucosal immunisation offers an attrac-
tive two-pronged approach as it stimulates both local and
systemic immunity [7]. Furthermore, it also offers the
potential for rapid administration in mass vaccination pro-
grams [14] without risk of injury and cross-infection
through contaminated needles [15]. In addition, with a
growing awareness for environmental impact, disposal of
needles, decontamination costs, and incineration waste
products has helped to influence development of mucosal
vaccines as a greener alternative [16].
Overall, PLc has been demonstrated to be immunogenic
against V. cholerae O1 [2] and also has immune adjuvant
effects when coadministered with Poli Vi. PLc is part of
the adjuvant family developed by the Finlay Institute,
AFPL (Adjuvant Finlay Proteoliposome) and named
AFPL2. Further studies are envisaged to evaluate the adju-
vant potential of AFPL2 with other antigens and using
other mucosal routes like oral to develop a multiple muco-
sal vaccine candidate against enteric pathogens.
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